アッヴィ SKYRIZI(リサンキズマブ-rzaa)、小児の乾癬性疾患でFDA承認

FDA approved SKYRIZI for children 6 years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis, including a new 55 mg pre-filled syringe for weight-based dosing in patients <40 kg. SKYRIZI is now the first and only IL-23 inhibitor approved in the U.S. for this pediatric population.

主要事実

提出: 2026年6月26日 20:50
イベント: FDA 承認
方向: ポジティブ
企業: ABBVアッヴィ
アセット: risankizumab
出典: 企業プレスリリース
信頼度: 出典あり

出典の抜粋

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease News provided by AbbVie Jun 26, 2026, 16:50 ET Share this article Share to X Share this article Share to X SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less than 40 kg SKYRIZI becomes the first and only IL-23 inhibitor approved in the U.S. for pediatric patients six years of age and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis NORTH CHICAGO, Ill. , June 26, 2026 /PRN

企業プレスリリース